<DOC>
	<DOCNO>NCT00333684</DOCNO>
	<brief_summary>Evaluate record change Quality Life psychological state affect study group follow treatment Bio-Alcamid . Evaluate safety efficacy Bio-Alcamid restore natural fullness contour face affected HIV drug-induced lipoatrophy . Pre-treatment classification post treatment record change perform , , Principal Investigator Treatment Specialist independently 'Blinded ' Co-Investigator post treatment Week 12 . Safety data Bio-Alcamid collect throughout duration study . Safety determine rate procedure-related event adverse experience associate use Bio-Alcamid .</brief_summary>
	<brief_title>Safety , Efficacy Psychological Effects Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid</brief_title>
	<detailed_description>Thirty ( 30 ) participant randomize portion study select classified moderate severe facial lipoatrophy base three investigator evaluation . These patient divide two group - The Treatment Group - 15 : At Day -1 , Treatment group establish inclusion/exclusion criterion consent form sign . At Day 0 complete QOL Surveys receive treatment Bio-Alcamid affect facial area ( ) . At Day 7 , return complete QOL Surveys allow CITS determine touch-up necessary . If , one touch-up session permit week 6 . The participant complete QOL Surveys efficacy assessment week 12 . The Treatment Group continue follow-up session week 24 , 48 , 60 96 week . Professional clinical photograph take visit . The Control Group - 15 : At Day -1 , Control group establish inclusion/exclusion criterion consent form sign . At Day 0 , complete QOL Surveys . They return visit baseline week 6 well complete QOL Surveys . At Week 12 , complete QOL Surveys receive BA treatment . At Week 13 , return complete QOL Surveys allow CITS determine touch-up necessary . If , one touch-up session permit week 18 . If , participant complete QOL Surveys efficacy assessment week 24 . The Control Group continue follow-up session week 48 , 60 , 96 104 week . Professional clinical photograph take visit .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Facies</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>Have moderate severe level facial lipoatrophy determine three investigstors If female childbearing potential ( menopausal least 1 year surgically sterile ) , negative urine pregnancy test prior study treatment willing use oral contraception another medically acceptable form contraception duration study Be able understand comply requirement study Be willing able provide write Informed Consent prior studyrelated procedure perform Agree refrain seek treatment lipoatrophy facial area participate study Are pregnant , lactating , try become pregnant Had prior therapy ( e.g. , permanent biodegradable injectable filler surgical correction facelift , etc . ) within 9 month prior entry study planning undergo therapy study Have active inflammation , infection , unhealed wound face Have contraindicate condition describe package insert product administer . Have history anaphylaxis multiple severe allergy . Have plan relocation study , would make followup visit impossible course study Used aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) within 1 week prior initial touchup treatment take concomitant anticoagulant therapy , antiplatelet therapy , history bleeding disorder Used overthecounter wrinkle product ( e.g. , alphahydroxy acid ) prescription treatment ( e.g. , Renova , RetinA , microdermabrasion , chemical peel ) facial area within 4 week prior study start . In addition , participant restrict use overthecounter wrinkle product prescription treatment facial area duration study . Have receive investigational product within 30 day prior study enrollment planning receive investigational product study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>